Vor Biopharma (VOR) Profit After Tax (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Profit After Tax data on file, last reported at -$747000.0 in Q1 2026.

• On a quarterly basis, Profit After Tax rose 97.7% year-over-year to -$747000.0 in Q1 2026; TTM through Mar 2026 was -$3.1 billion, a 11837.81% decrease from a year earlier, with the FY2025 full-year figure at -$696.0 million, down 703091.92% from the prior year.
• Profit After Tax for Q1 2026 stood at -$747000.0, up from -$696.0 million in the prior quarter.
• Over the last five years, Profit After Tax for VOR reached as high as $92.3 million in Q4 2023 and fell as low as -$1.6 billion in Q2 2025.
• Historically, Profit After Tax has averaged -$185.2 million across 5 years, with a median of -$23.9 million in 2022.
• Across the five-year window, Profit After Tax surged 486.01% in 2023 and slumped 9256976.47% in 2025, its largest moves.
• Year by year, Profit After Tax stood at -$23.9 million in 2022, then jumped by 486.01% to $92.3 million in 2023, then dropped by 6.65% to $86.2 million in 2024, then plunged by 907.78% to -$696.0 million in 2025, then surged by 99.89% to -$747000.0 in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$747000.0 in Q1 2026, -$696.0 million in Q4 2025, and -$812.7 million in Q3 2025.